

Project Title

Telerehabilitation Using A 2D Planar Arm Rehabilitation Robot for Hemiparetic Stroke
Upper Limb: A Pilot Feasibility Trial

Project Lead and Members

Project Lead: Karen SG, Chua

Project Members: Poo Lee Ong, Christopher WK Kuah, Tegan K Plunkett, Chwee Yin
Ng, Wei Binh Chong, Lay Wai Khin, Kim Huat Goh, Gabriel A Ollinger, Asif Hussain

Organisation(s) Involved

Institute of Rehabilitation Excellence (IREx), Tan Tock Seng Hospital Rehabilitation
Centre Singapore, Lee Kong Chian School of Medicine, Nanyang Technological
University, Singapore, Clinical Research and Innovation Office, Nanyang Business
School, Nanyang Technological University, Singapore, Articares Pte Ltd, Singapore

Healthcare Family Group(s) Involved in this Project

Allied Health

Applicable Specialty or Discipline

Rehabilitation Therapy, Occupational Therapy, Physiotherapy, Neurology

Project Period

Start date: 3 March 2022

Completed date: 1 June 2023

Aim

Evaluate the feasibility, safety, efficacy, and cost-effectiveness of clinic-to-home
telerehabilitation using a 2D portable planar arm robot for hemiparetic stroke
patients.

Background

Stroke patients often face chronic upper extremity impairments. Robotic-assisted therapy could address these limitations through telerehabilitation at home.

Methods

A prospective pilot study was conducted with stroke patients, using a home-based 2D planar robot (HMAN) for 30 days under carer supervision, with telemonitoring and assessment at different time points (baseline, 5 weeks, 12 weeks, 24 weeks)

Results

Statistically significant improvements in Fugl-Meyer Motor Assessment (FMA) and Action Research Arm Test (ARAT) scores were observed at 5 weeks and 24 weeks. A reduction in direct therapy costs for home-based rehabilitation compared to clinic-based programs

Lessons Learnt

Telerehabilitation with robotics can be both cost-effective and efficacious in improving upper limb rehabilitation post-stroke

Conclusion

The study demonstrated the feasibility and potential cost-saving benefits of home-based robotic therapy for stroke patients, reducing direct costs of rehabilitation.

Additional Information:

Mean home gameplay time was 1.04 ± 0.35 hours per day.

Project Category

Care Continuum

Intermediate and Long Term & Community Care, Home Care

Technology

Assistive Technology, Robotic

Care & Process Redesign

Productivity, Cost Saving, Value Based Care,

Additional Information

No adverse events were reported, and the study was funded by CHISEL Temasek Fund.

Keywords

Telerehabilitation, Stroke, Robotics, Upper Limb, Feasibility Study, Robotics, Hemiparetic Stroke, Upper Limb Rehabilitation, Cost-Effectiveness

Name and Email of Project Contact Person(s)

Name: Karen Chua Sui Geok

Email: karen_chua@ttsh.com.sg

Telerehabilitation using a 2D planar arm rehabilitation robot for hemiparetic stroke upper limb: A pilot feasibility trial

Karen SG, Chua^{1,2}, Poo Lee, Ong^{1,2}, Christopher WK, Kuah¹, Tegan K, Plunkett¹, Chwee Yin, Ng¹, Wei Binh, Chong^{1,3}, Lay Wai, Khin³, Kim Huat, Goh⁴, Gabriel A, Ollinger⁵, Asif Hussain⁵

1. Institute of Rehabilitation Excellence (IREx), Tan Tock Seng Hospital Rehabilitation Centre Singapore, 2. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 3. Clinical Research and Innovation Office, Tan Tock Seng Hospital Singapore, 4. Nanyang Business School, Nanyang Technological University, Singapore, 5. Articares Pte Ltd, Singapore

Introduction

A proof-of-concept study using a portable 2-D planar robot*, was conducted to evaluate the feasibility, safety and efficacy of home-based robot-aided telerehabilitation for stroke upper limb rehabilitation.

Methods

Study design: Prospective pilot single-arm study. Ethics approval was granted by NHG DSRB. (2021/00156, www.clinicaltrials.gov NCT05322837)

Study setting: Outpatient rehabilitation clinic of a public hospital.


Participants' Inclusion criteria: Confirmed strokes aged >21 years and >28 days duration, upper limb Fugl-Meyer Motor Assessment (FMA) 10-60/66, MoCA >21/30, supported sitting tolerance >60 minutes, with availability of a stable home and carer.

Participants' Exclusion criteria: Medical contraindications, pregnancy, life expectancy < 6 months, severe upper limb pain score >5/10 or spasticity, fixed contractures, hemi anesthesia, neglect, active fractures or arthritis.

Study Interventions: The HMAN* end-effector robot was set up in subjects' homes for carer-supervised HMAN training for 30 consecutive days, combined with asynchronous tele monitoring and 1 session of clinic conventional therapy (OT). (see Figure 1 for study protocol)

Main Outcome measures: Performed by senior occupational therapists at weeks 0 (baseline), 5 (post-training), 12 (follow-up) and 24 (follow-up).

Figure 1. Study protocol



HMAM robot



Outcomes: Total game play time, defined as any period spent inside any exergames via cloud; FMA (motor), Action Research Arm Test (ARAT), upper limb self-efficacy test (UPSET), WHO-stroke specific QOL (SSQOL) and cost utilisation analysis.

Statistical Analyses: Non-parametric analysis using Wilcoxon Sign rank (SPSS ver 26 (Armonk)). A two-tailed test level of significance was set at $P < 0.05$.


Table 1. Summary baseline characteristics (N=12)

Variables; mean , SD (range)		
Age (years)	59.4 ± 9.49 (46 - 76)	
Gender, n (%)	Male: n=9 (75%)	Female: n=3 (25%)
Stroke type, n(%)	Infarct: n=9 (75%)	Haemorrhage: n=3 (25%)
Side of hemiplegia, n(%)	Right: n=6 (50%)	Left: n=6 (50%)
Duration post stroke (weeks) median (QR)	38.6 (25.4, 79.6)	
FMA Score/66	42.1 ± 13.2 (15 - 56)	
ARAT Score/57	25.4 ± 19.5 (3 - 55)	
Grip Strength affected hand (kg)	7.8 ± 2.8	
Stroke Specific Quality of Life/245	185.3 ± 32.8 (122 - 237)	
Upper Limb Self Efficacy Test/200	76.3 ± 48.1 (11 - 160)	

Results


Table 1 shows baseline characteristics of 12 participants. No adverse events were reported. One drop-out occurred during follow-up.

Figure 2. Aggregated Game Play Duration by Week (N=12)




Mean (SD) total game play / day was 1.04 ± 0.35 hours. Week 4 epoch included a total of 9 days game play. Comparing week 1 to 4, game play duration was not significant ($P = 0.139$). (Figure 2)

Figure 3. Change in FMA scores by time point (N=12)




Comparing FMA, significant gains were observed across time; Δ FMA 2.4 at week 5 (FMA 44.5 ± 13.9), from baseline (FMA 42.1 ± 13.2 , $P < 0.05$), and Δ FMA 3.7 at week 24 (FMA 45.8 ± 14.1 , $P < 0.05$). (Figure 3)

Figure 4. Change in ARAT scores by time point (N=12)



Comparing ARAT, significant gains were observed across time; Δ ARAT 2.6 at week 5 (ARAT 28.0 ± 20.3 , $P < 0.05$), from baseline (25.4 ± 19.5), and Δ ARAT 4.8 at week 24 (ARAT 30.2 ± 21.6 , $P < 0.05$). (Figure 4)

Figure 5. Comparison of Mean Costs by Programme Type (N=12)



Comparing programme type, lower direct costs for HMAN (home) SGD2,050.40 vs OT (clinic) SGD2,826.10 ($P = 0.0409$) vs HMAN (clinic) SGD2,917.20 ($P = 0.0505$) were observed. (Figure 5)

Discussion & Conclusion

This pilot study supports the feasibility, safety and efficacy of a clinic to home telerehabilitation arm robot with reduction in direct therapy costs.



Telerehabilitation using a home-based 2D planar arm rehabilitation robot for hemiparetic stroke:

A pilot feasibility trial reporting cost effectiveness



ARTICARES

Authors: Karen SG, Chua*^{1,2}, Lay Wai, Khin³, Kim Huat, Goh⁴ Poo Lee, Ong^{1,2}, Christopher WK, Kuah¹, Tegan K, Plunkett¹, Chwee Yin, Ng¹, Wei Binh, Chong¹, Jaclyn AM Low¹, Gabriel A, Ollinger⁵, Asif Hussain⁵

Affiliations: 1. Institute of Rehabilitation Excellence (IREx), Tan Tock Seng Hospital Rehabilitation Centre, Singapore; 2. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; 3. Clinical Research and Innovation Office, Tan Tock Seng Hospital Singapore; 4. Nanyang Business School, Nanyang Technological University, Singapore; 5. Articares Pte Ltd, Singapore.

BACKGROUND & AIMS

Post-stroke upper extremity (UE) impairments often persist into the chronic phase.¹ The majority of UE recovery occurs beyond hospital discharge when intensity of rehabilitation interventions needed to drive neuroplasticity wanes.¹ Minimally-assisted Robotics-assisted therapy (RAT) may provide effective solutions.^{2,3} We evaluated the feasibility, safety, efficacy and cost effectiveness analysis (CEA) of clinic-to-home telerehabilitation using a 2D portable planar arm robot.


MATERIALS and METHODS

A prospective pilot study was carried out from 3 March 2022 to 1 June 2023 in a rehabilitation outpatient clinic and participants' homes. The HMAN® (www.articares.com), was deployed in participants' homes (HMAN@Home) for 30 consecutive days under carers' supervision. Cloud-based telemonitoring was performed twice-weekly to monitor training duration & intensity by occupational therapist (OT) and patients did not visit the clinic during these 30 days. (Figure 1)

Inclusion criteria were medically-stable stroke >28 days, hemiparetic UE weakness (Fugl-Meyer Motor Assessment (FMA) 10-60/66), presence of caregiver and stable home situation. Exclusion criteria were arm pain >4/10, elbow flexors modified Ashworth scale (MAS) spasticity >2 or sitting tolerance <60 minutes.

Outcome measures at baseline, weeks 5 (end-training), 12 & 24 included FMA, Action Research Arm Test (ARAT), Jamar dynamometer grip strength (kg), WHO-SSQOL and Upper Limb Self-Efficacy Test (UPSET). (Figure 1)

Figure 1. Study protocol



Total, direct and indirect cost components comparing conventional occupational therapy (COT) and RAT@Clinic were computed based on participants' retrospective billed clinical programme costs during study duration. Direct costs included onboarding & home visits and outcomes/telemonitoring by OT, HMAN@Home and supporting furniture rental. Indirect costs included participants' and carers' transportation, clinic waiting & payment time, home-related carers' time, utilities and WiFi. (Table 1)

Table 1: Comparison of component costs (SGD) by programme type (N=12)

Mean(SD) S\$/ participant	COT Matched to RAT@ clinic	RAT@Clinic	HMAN@Home Current intervention
Total (A+B)	3,191.04 (1,258.50)	3,282.14 (1,386.05)	2,416.92 (253.26)
(A) Direct costs	2,826.12 (1,173.91)	2,917.22 (1,312.51)	2,187.61 (262.62)
-Programme cost	2,826.12 (1,173.91)	2,917.22 (1,312.51)	2,050.39 (232.71)
-Telemonitoring cost	0.00	0.00	137.22 (83.99)
(B) Indirect costs	364.92 (125.34)	364.92 (125.32)	229.31 (53.56)
-Waiting Time	0.00*	0.00*	29.53 (55.20)
-Transportation	364.92 (125.34)	364.92 (125.32)	92.03 (35.30)
-Home related**	0.00	0.00	107.75 (30.75)

Legend: *not available due to retrospective collection; ** home-related carer's time, utilities & WiFi

Statistical analyses:

Adjusted clinical effect sizes (FMA) for HMAN@Home, COT and RAT@Clinic were calculated using multivariate mixed random effect models and clinically important variables were adjusted in the models. CEA was carried out using model-based, estimated individual predicted clinical effect sizes, and direct, indirect and total costs for 3 unique treatment pathways.

DISCUSSION & CONCLUSION

Our study findings support the preliminary feasibility, safety, efficacy and cost-effectiveness of HMAN@Home compared with COT. Telerehabilitation robotics may potentially provide an adjunctive stroke rehabilitation pathway.


References:
1. van Vliet P, Tavener M, van Wijk FM, Alt Murphy M. Editorial: Home-based training to reduce upper limb functional impairment post-stroke. *Front Neurol.* 2023 Oct 24;14:1309954. doi: 10.3389/fneur.2023.1309954. PMID: 37941575; PMCID: PMC10628668.
2. Budhota A, Chua KSG, Hussain A, et al. Robotic Assisted Upper Limb Training Post Stroke: A Randomized Control Trial Using Combinatory Approach. *Front Neurol.* 2021 Jun 2;12:622014. doi: 10.3389/fneur.2021.622014
3. Wagner TH, Lo AC, Peduzzi P, Bravata DM, Huang GD, Krebs HI, Ringer RJ, Federman DG, Richards LG, Haselkorn JK, Wittenberg GF, Volpe BT, Bever CT, Duncan PW, Siroka A, Guarino PD. An economic analysis of robot-assisted therapy for long-term upper-limb impairment after stroke. *Stroke.* 2011 Sep;42(9):2630-2. doi: 10.1161/STROKEAHA.110.606442. Epub 2011 Jul 14. PMID: 21757677; PMCID: PMC4445835.

RESULTS

Altogether, 12 stroke participants were enrolled; 9 (75%) males, 8 (66.7%) infarcts, mean (SD) age 59.4 (9.5) years, mean stroke duration 88.5 ± 137.2 (13.4 – 501) weeks, baseline FMA 42.1 (13.2) and ARAT 25.4 (19.5). Mean (SD) total home game play duration / day was 1.04 ± 0.35 hour (cloud data, Figure 2).

Significant post-training gains were observed; ΔFMA 2.4 at end-training week 5, (P < 0.05) and Δ FMA 3.7 at follow-up week 24 (P < 0.05); ΔARAT 2.6 at end-training week 5 (P < 0.05) and ΔARAT 4.8 at follow-up week 24 (P < 0.05).


Figure 2. HMAN training duration by week (hours) based on cloud data (N=12)



Mean individual cost savings by programme of **-24.3%** were observed for HMAN@Home (SGD2,416.92) compared to RAT@Clinic (SGD3,282.14), (P = 0.62) (table 1) The adjusted predicted mean values of FMA for HMAN@Home, COT (control) and RAT@Clinic were 45.75 (95% CI: 40.53 – 50.97), 40.36 (95%CI: 36.28 – 44.44) and 45.52 (95%CI: 40.98 – 50.06) respectively. (Figure 3)

CEA analysis comparing HMAN@Home with COT (control) demonstrated that HMAN@Home resulted in a positive incremental effect of ΔFMA+5.4 with a negative incremental cost effectiveness ratio (ICER) of **-143.73 SGD** per cure. These results indicated that HMAN@Home was not only cost-effective but cost saving.

Figure 3 Cost-effectiveness savings comparing HMAN@Home and COT



FMA Outcome
Cost = -774.14 (-ve cost/cost saving) (2416.92 – 3191.06)
Effect = +5.39 (+ve gain) (45.75 – 40.36)
ICER = -143.73/cure (cost saving): 6 weeks duration

